# HAIC Combined With Sintilimab Plus Bevacizumab Biosimilar for Advanced Hepatocellular Carcinoma (TASK-03)

> **NCT06860490** · PHASE2 · RECRUITING · sponsor: **Fudan University** · enrollment: 164 (estimated)

## Conditions studied

- Hepatocellular Carcinoma (HCC)

## Interventions

- **DRUG:** Sintilimab
- **DRUG:** Bevacizumab Biosimilar
- **PROCEDURE:** HAIC

## Key facts

- **NCT ID:** NCT06860490
- **Lead sponsor:** Fudan University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-03-18
- **Primary completion:** 2027-03-10
- **Final completion:** 2028-03-10
- **Target enrollment:** 164 (ESTIMATED)
- **Last updated:** 2026-04-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06860490

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06860490, "HAIC Combined With Sintilimab Plus Bevacizumab Biosimilar for Advanced Hepatocellular Carcinoma (TASK-03)". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT06860490. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*